Identifying the precise mechanism could have broad implications for diseases treated with mTOR inhibitors (e.g., cancer, autoimmune disorders, and transplantation) and emerging GSK3-targeted therapies (e.g., Alzheimer’s, diabetes, and bipolar disorder). The gene discussed is MTOR; the disease is autoimmune disease.